Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 175-183

  Ierano, Caterina ^a,b   Basseville, Agnes ^a   To, Kenneth K W ^a,c   Zhan, Zhirong ^a   Robey, Robert W ^a   Wilkerson, Julia ^a   Bates, Susan E ^a   Scala, Stefania ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CXCL12; CXCR4; Histone deacetylase inhibitor; Migration; Romidepsin

Indexed keywords

APICIDIN; CHEMOKINE RECEPTOR CXCR4; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; ROMIDEPSIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CELL STRAIN MCF 7; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GLIOMA CELL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

CXCL12; CXCR4; HISTONE DEACETYLASE INHIBITOR; MIGRATION; ROMIDEPSIN;

CELL LINE, TUMOR; CHEMOKINE CXCL12; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTORS, CXCR4; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR;

EID: 84873445588     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22957     Document Type: Article

References (48)

1. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16:2927-31; PMID:20484021; http://dx.doi.org/10.1158/1078-0432. CCR-09-2329.
2. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65:6178-88; PMID:16024619; http://dx.doi.org/10.1158/0008-5472.CAN-04-4406.
3. Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 2008; 214:464-71; PMID:18189328; http://dx.doi.org/10.1002/path.2310.
4. do Carmo A, Patricio I, Cruz MT, Carvalheiro H, Oliveira CR, Lopes MC. CXCL12/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol Ther 2010; 9:56-65; PMID:19923906; http://dx.doi.org/10.4161/cbt.9.1.10342.
5. Carlisle AJ, Lyttle CA, Carlisle RY, Maris JM. CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation. Mol Cancer 2009; 8:126; PMID:20028517; http://dx.doi.org/10.1186/1476-4598-8-126.
6. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006; 12:2795-803; PMID:16675573; http://dx.doi.org/10.1158/1078-0432.CCR-05-2142.
7. Engl T, Relja B, Marian D, Blumenberg C, Müller I, Beecken WD, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006; 8:290-301; PMID:16756721; http://dx.doi.org/10.1593/neo.05694.
8. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11:1835-41; PMID:15756007; http://dx.doi.org/10. 1158/1078-0432.CCR-04-1887.
9. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, et al. Increased survival, proliferation and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64:8420-7; PMID:15548713; http://dx.doi.org/10.1158/0008-5472.CAN-04-1343.
10. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167:1676-86; PMID:12626353; http://dx.doi.org/10.1164/rccm.200301-071OC.
11. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62:5930-8; PMIDHYPERLINK "http://www.ncbi. nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&li st-uids=12384559&dopt=Abstract:12384559.
12. Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002; 86:1250-6; PMID:11953881; http://dx.doi.org/10.1038/sj.bjc.6600221.
13. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 5:56; PMID:17083723; http://dx.doi.org/10.1186/ 1476-4598-5-56.
14. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425:307-11; PMID:13679920; http://dx.doi.org/10.1038/nature01874.
15. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107:600-8; PMID:19459166; http://dx.doi.org/10. 1002/jcb.22185.
16. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111-20; PMID:17594194; http://dx.doi.org/10.1517/13543784.16.7.1111.
17. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98:2865-8; PMID:11675364; http://dx.doi.org/10.1182/blood.V98.9.2865.
18. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007; 13:30-9; PMID:17464244; http://dx.doi.org/10. 1097/PPO.0b013e31803c73cc.
19. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008; 180:1131-6; PMID:18639283; http://dx.doi.org/10.1016/j.juro.2008.04.136.
20. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-28; PMIDHYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&list-uids=11895901&dopt=A bstract:11895901.
21. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006; 5:57-60; PMID:16859580; http://dx.doi.org/10.3816/CGC. 2006.n.018.
22. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2009; 13(8B):2376-85; PMID:18657224; http://dx.doi.org/10.1111/j.1582-4934.2008.00436.x.
23. Crazzolara R, Jöhrer K, Johnstone RW, Greil R, Kofler R, Meister B, et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 2002; 119:965-9; PMID:12472574; http://dx.doi.org/10.1046/j.1365-2141.2002.03955.x.
24. Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010; 95:1136-43; PMID:20145270; http://dx.doi.org/10.3324/haematol.2009.013847.
25. Gul H, Marquez-Curtis LA, Jahroudi N, Lo J, Turner AR, Janowska-Wieczorek A. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev 2009; 18:831-8; PMID:18847317; http://dx.doi.org/10.1089/scd.2008.0235.
26. Gul H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A. Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2010; 34:235-42; PMID:19539992; http://dx.doi.org/10.1016/j.leukres. 2009.05.014.
27. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005; 65:1800-7; PMID:15753377; http://dx.doi.org/10.1158/0008-5472.CAN-04-3531.
28. Kim SW, Kim HY, Song IC, Jin SA, Lee HJ, Yun HJ, et al. Cytoplasmic trapping of CXCR4 in hepatocellular carcinoma cell lines. Cancer Res Treat 2008; 40:53-61; PMID:19688049; http://dx.doi.org/10.4143/crt.2008.40.2.53.
29. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006; 12:1547-55; PMID:16533780; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1423.
30. Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol 2007; 74:1702-12; PMID:17904532; http://dx.doi.org/10.1016/j.bcp.2007. 08.025.
31. Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM, Kim J. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 2010; 39:81-7; PMID:19820417; http://dx.doi.org/10.1097/MPA.0b013e3181bb2ab7.
32. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768:952-63; PMID:17169327; http://dx.doi.org/10.1016/j.bbamem.2006. 11.002.
33. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-95; PMID:19787002; http://dx.doi.org/10.1038/ nrclinonc.2009.129.
34. Ahr B, Denizot M, Robert-Hebmann V, Brelot A, Biard-Piechaczyk M. Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation. J Biol Chem 2005; 280:6692-700; PMID:15615703; http://dx.doi.org/10.1074/jbc. M408481200.
35. Pfeiffer M, Hartmann TN, Leick M, Catusse J, Schmitt-Graeff A, Burger M. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer 2009; 100:1949-56; PMID:19455144; http://dx.doi.org/10.1038/ sj.bjc.6605068.
36. Fernandis AZ, Prasad A, Band H, Klösel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004; 23:157-67; PMID:14712221; http://dx.doi.org/10.1038/sj.onc.1206910.
37. Lin KT, Yeh SH, Chen DS, Chen PJ, Jou YS. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 2005; 12:803-13; PMID:16132114; http://dx.doi.org/10.1007/s11373-005-9005-2.
38. Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, et al. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol 2008; 28:3219-35; PMID:18332107; http://dx.doi.org/10.1128/MCB.01516-07.
39. To KK, Polgar O, Huff LM, Morisaki K, Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 2008; 6:151-64; PMID:18234970; http://dx.doi.org/10.1158/1541-7786.MCR-07-0175.
40. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 2008; 68:5753-9; PMID:18632628; http://dx.doi.org/10.1158/0008-5472.CAN-08-0700.
41. Park H, Im JY, Kim J, Choi WS, Kim HS. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med 2008; 21:325-33; PMIDHYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&lis t-uids=18288380&dopt=Abstract:18288380.
42. Chen J, Rusnak M, Lombroso PJ, Sidhu A. Dopamine promotes striatal neuronal apoptotic death via ERK signaling cascades. Eur J Neurosci 2009; 29:287-306; PMID:19200235; http://dx.doi.org/10.1111/j.1460-9568.2008.06590.x.
43. Pettersson F, Couture MC, Hanna N, Miller WH. Enhanced retinoid-induced apoptosis of MDAMB-231 breast cancer cells by PKC inhibitors involves activation of ERK. Oncogene 2004; 23:7053-66; PMID:15273718; http://dx.doi.org/10.1038/sj. onc.1207956.
44. Zhang XF, Wang JF, Matczak E, Proper JA, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 2001; 97:3342-8; PMID:11369622; http://dx.doi.org/10.1182/blood. V97.11.3342.
45. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65:520-7; PMID:14978230; http://dx.doi.org/10.1124/mol.65.3.520.
46. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281:5612-22; PMID:16377638; http://dx.doi.org/10.1074/jbc.M507213200.
47. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003; 63:3069-72; PMIDHYPERLINK "http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrie ve&db=PubMed&list-uids=12810630&dopt=Abstra ct:12810630.
48. Matsumoto Y, Motoki T, Kubota S, Takigawa M, Tsubouchi H, Gohda E. Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid. Biochem Biophys Res Commun 2008; 366:110-6; PMID:18053801; http://dx.doi.org/10.1016/j.bbrc.2007.11.089.